Related Experiment Video
Updated: Apr 30, 2026
09:27
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
Published on: June 17, 2016
11.8K
Summary
Methyldopa, a hypertension drug, can cause severe hepatitis. Discontinuing methyldopa rapidly improves liver health, even in cases mimicking chronic hepatitis.
Area of Science:
- Hepatology
- Clinical Pharmacology
Background:
- Hypertension management often involves medications like methyldopa.
- Drug-induced liver injury (DILI) is a significant clinical concern.
- Methyldopa has been associated with various adverse effects, including hepatotoxicity.
Observation:
- Six cases of severe hepatitis linked to methyldopa therapy were observed over two years.
- One patient experienced recurrent hepatitis upon inadvertent drug re-administration.
- A fatal outcome occurred in one patient due to massive hepatic necrosis.
Findings:
- Liver biopsies in survivors showed severe hepatitis, histologically similar to early chronic aggressive hepatitis.
- Discontinuation of methyldopa led to rapid and complete recovery in all affected patients.
- The study highlights the potential for methyldopa to cause severe, potentially fatal, liver injury.
Implications:
- Clinicians should consider methyldopa as a potential cause of hepatitis in patients on this medication.
- Prompt drug cessation is crucial upon detecting constitutional symptoms or biochemical evidence of hepatitis.
- Investigating methyldopa's role is essential in patients presenting with histological patterns suggestive of chronic aggressive hepatitis.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
357
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
357
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
01:25Hepatitis
81
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
81
01:29Hepatic Encephalopathy
46
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
46